Is CSL worth $342 per share?
UBS continues to see upside potential from Australia’s largest listed company: CSL.
Why the CSL share price may be undervalued
It's been an interesting period for market darling CSL: in the last month the stock has fallen around 5%, though trended positively over the last five trading sessions.
This comes after the biotech giant hit an all-time high of $342.75 per share in February and upgraded its full-year profit guidance during its H1 results.
Mind you, although CSL has seen its share price fall in the short-term, it remains Australia’s largest listed company, with a market capitalisation of ~$128 billion. Moreover, while UBS notes CSL is currently trading at a significant earnings premium to the market – the investment bank still believes the stock has room to run higher.
UBS has a Buy rating and a 12-month price target of $342 per share on CSL – implying upside potential of around ~18% from the stock’s last traded price – and suggesting that the investment bank believes CSL is undervalued at current price levels.
Industry data at a glance
Surveying the recent data from the Plasma Protein Therapeutics Association (PPTA) – covering February – on a 12-month roll, UBS notes that IG (immunoglobulin) volumes increased 14.7% in February, up from the 13.6% increase they witnessed in January. By comparison, this recent data release showed that Albumin (Human) 5% volumes were sluggish, growing just 3.7% in February, against growth of 4.7% in January.
Finally, Albumin (Human) 25% volumes grew 3.0% in February.
Looking forward, UBS said that they are ‘currently forecasting 15% decline in plasma collection in the April-June period with recovery thereafter.’
Positively, the investment bank did flag that:
‘However with a number of US states moving to ease shelter-at home regulations, raw plasma supply disruption may be short-lived. Notwithstanding plasma supply risk, CSL remains our preferred health care exposure based on the robust demand profile for products […] and relatively low level of gearing.’
Events for investors to watch out for
Finally, UBS notes that two potential near-term catalysts for CSL's share price include: the March PPTA data report, set to be released around 20 July; and CSL's full-year, FY20 results, set to be released 19 August.
How to trade CSL – long and short
What do you think: is UBS’s price target for CSL off the mark or is it justified? Trade accordingly. For example, you can trade CSL shares and other large-cap ASX stocks – both LONG and SHORT – through IG’s world-class trading platform now.
To buy (long) or sell (short) CSL with CFDs, follow these simple steps:
IGA, may distribute information/research produced by its respective foreign affiliates within the IG Group of companies pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the research is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, IGA accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact IGA at 6390 5118 for matters arising from, or in connection with the information distributed.
The information/research herein is prepared by IG Asia Pte Ltd (IGA) and its foreign affiliated companies (collectively known as the IG Group) and is intended for general circulation only. It does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. You should take into account your specific investment objectives, financial situation, and particular needs before making a commitment to trade, including seeking advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit.
Please see important Research Disclaimer.
Seize a share opportunity today
Go long or short on thousands of international stocks.
- Increase your market exposure with leverage
- Get spreads from just 0.1% on major global shares
- Trade CFDs straight into order books with direct market access
Live prices on most popular markets
Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.